Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
In re Aveo Pharmaceuticals Inc. Securities Litigation
Case Number:
1:13-cv-11157
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
-
May 30, 2018
Investors Clinch $18M Deal With Aveo, With 30% For Attys
A Massachusetts federal judge on Wednesday granted final approval to an $18 million settlement Aveo Pharmaceuticals Inc. reached with investors to close a five-year-old class action stock-drop case that was dismissed twice before it was certified.
-
May 10, 2018
Pomerantz, Shapiro Seek $5M Fees For $18M Aveo Stock Deal
New York-based law firm Pomerantz LLP and Boston firm Shapiro Haber & Urmy LLP asked a Massachusetts federal judge late Wednesday to approve a $5 million fee request after representing investors in a twice-dismissed stock drop suit against Aveo Pharmaceuticals Inc. that ended in an $18 million deal.
-
February 02, 2018
Aveo Agrees To $18M Deal To End Cancer Drug Investor Suit
Investors in Aveo Pharmaceuticals Inc. on Friday asked a Massachusetts federal judge for an initial sign-off on a deal worth more than $17.7 million that would resolve a class action alleging the drugmaker hid U.S. Food and Drug Administration concerns about tivozanib, Aveo's drug candidate for treating kidney cancer.
-
November 15, 2017
Aveo Investors Get Certification In Cancer Drug Suit
A Massachusetts federal judge on Tuesday granted class certification to a group of investors claiming Aveo Pharmaceuticals Inc. misled them about concerns the U.S. Food and Drug Administration had about the company's kidney cancer drug.
-
June 29, 2017
Aveo Investors Want Class Cert. In Kidney Cancer Drug Spat
Investors claiming Aveo Pharmaceuticals Inc. hid U.S. Food and Drug Administration concerns about its kidney cancer drug from them asked a Massachusetts federal court Thursday to certify their proposed class, calling it a "textbook example" of a securities case warranting class action treatment.
-
March 20, 2015
Aveo Kicks Investor Suit Over Losses From Kidney Drugs
A Massachusetts federal judge on Friday dismissed a proposed shareholder class action accusing Aveo Pharmaceuticals Inc. of deceiving investors about the riskiness of its kidney cancer drug, finding the investors have failed to show the drugmaker's management knowingly defrauded them.
-
May 10, 2013
Aveo Hid Kidney Drug's Higher Death Risk, Shareholder Says
Aveo Pharmaceuticals Inc. was hit with a proposed class action Thursday accusing it of hiding that the U.S. Food and Drug Administration found that its kidney cancer treatment drug Tivozanib increased patients' risk of death more than competitors and that Aveo's trials for the drug were inadequate.